HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marelli, D. Articles by Kubak, B. Search for Related Content PubMed PubMed Citation Articles by Marelli, D. Articles by Kubak, B. Related Collections Transplantation - heart

Ann Thorac Surg 2002;74:1558-1567
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Seventeen-year experience with 1,083 heart transplants at a single institution

^a Heart Transplant Program, University of California, Los Angeles, Los Angeles, California, USA

* Address reprint requests to Dr Marelli, UCLA School of Medicine, 10833 Le Conte Ave, 62-266 CHS, Box 951741, Los Angeles, CA 90095-1741, USA.
e-mail: dmarelli{at}mednet.ucla.edu

Presented at the Thirty-eighth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2002.

BACKGROUND: Heart transplantation is the most accepted treatment for end-stage heart disease. A review of 1,083 consecutive transplants (1984 to 2001) was undertaken.

METHODS: Adult recipients were divided into quartiles. The last 540 transplants were combined. Three eras were created from these, 1984 to 1991, 1991 to 1995, and 1995 to 2001, with three age groups: 0 to 18 years, 19 to 61 years, and 62 to 74 years. All patients have at least 1 year of follow-up time. End points were survival, rejection, and graft coronary artery disease.

RESULTS: There were 1,012 patients. Donor age, graft ischemic time, and the proportion of elderly recipients and nonstandard donor hearts have increased in the current era. Actuarial 60-month survivals of recipients after 1995 were 80.7% (0 to 18 years); 75.3% (19 to 61 years); and 76.2% (>62 years). The current era children and younger adult groups demonstrated improved results when compared with previous eras (p = 0.003 and p = 0.05). Rejection episodes equal to or greater than ISHLT grade 3A per person per year improved to 0.15 in the current era (p < 0.001). During the three eras, older recipients (>62 years) demonstrated fewer episodes of rejection when compared with other adults (0.13 versus 0.58, p = 0.03). Deaths attributed to graft coronary artery disease decreased from 11% to 5% from era 2 to era 3. Regression analysis revealed a mild effect of donor age on survival and graft coronary artery disease (hazard ratio = 1.02, p = 0.001; hazard ratio = 1.039, p < 0.001, respectively). Recipient predictors of graft coronary artery disease were diagnosis of ischemic cardiomyopathy (hazard ratio = 1.6, p = 0.014) and congenital heart disease (hazard ratio = 3.41, p = 0.02).

CONCLUSIONS: Improved survival in the current era may be attributed to better organ preservation, improved immunosuppression and control of infection, and less life-threatening graft coronary artery disease.

This article has been cited by other articles:

				C. E. Canter, R. E. Shaddy, D. Bernstein, D. T. Hsu, M. R.K. Chrisant, J. K. Kirklin, K. R. Kanter, R. S.D. Higgins, E. D. Blume, D. N. Rosenthal, et al. Indications for Heart Transplantation in Pediatric Heart Disease: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, February 6, 2007; 115(5): 658 - 676. [Abstract] [Full Text] [PDF]

				R. L. Benza, B. K. Rayburn, J. A. Tallaj, C. S. Coffey, L. J. Pinderski, S. V. Pamoukian, and R. C. Bourge Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest, April 1, 2006; 129(4): 1009 - 1015. [Abstract] [Full Text] [PDF]

				F. A. Mitropoulos, J. Odim, D. Marelli, K. Karandikar, D. Gjertson, A. Ardehali, J. Kobashigawa, and H. Laks Outcome of hearts with cold ischemic time greater than 300minutes. A case-matched study Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 143 - 148. [Abstract] [Full Text] [PDF]

				N. A. G. Solomon, J. R. McGiven, P. M. Alison, P. N. Ruygrok, D. A. Haydock, H. A. Coverdale, and T. M. West Changing donor and recipient demographics in a heart transplantation program: influence on early outcome Ann. Thorac. Surg., June 1, 2004; 77(6): 2096 - 2102. [Abstract] [Full Text] [PDF]

				J. A. Morgan, R. John, D. M. Mancini, and N. M. Edwards Should heart transplantation be considered as a treatment option for patients aged 70 years and older? J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1817 - 1819. [Full Text] [PDF]

				J. A. Morgan, R. John, A. D. Weinberg, R. Remoli, A. R. Kherani, D. W. Vigilance, B. M. Schanzer, G. Bisleri, D. M. Mancini, M. C. Oz, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis Ann. Thorac. Surg., December 1, 2003; 76(6): 1982 - 1987. [Abstract] [Full Text] [PDF]

				J. A. Morgan, R. John, A. D. Weinberg, A. R. Kherani, N. J. Colletti, D. W. Vigilance, F. H. Cheema, G. Bisleri, T. Cosola, D. M. Mancini, et al. Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1624 - 1633. [Abstract] [Full Text] [PDF]